Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. d/b/a Drug Channels Institute. P.S. Join my nearly 30,000 (!) to 1:30 p.m.

Biosimilars 98

Biosimilars Pharmacy Drugs Marketing 98

Drug Channels

NOVEMBER 15, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The Outlook 2022 marks our third annual outlook webinar.

Specialty Pharmacies 72

Specialty Pharmacies Biosimilars Drugs Pharmacy 72

Drug Channels

DECEMBER 11, 2023

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2024 live video webinar. CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Biosimilars 75

Biosimilars Pharmacy Production Marketing 75

Drug Channels

MARCH 30, 2023

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version.

Biosimilars 75

Biosimilars Pharmacy Drugs Production 75

Drug Channels

APRIL 19, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. An ironic postcript: Less than two months after my article was published, Cigna CEO David Cordani bragged about the cost savings from "aggressive adoption" of biosimilars.

Biosimilars 75

Biosimilars Production FDA Drugs 75

Drug Channels

MAY 30, 2023

d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Summer unofficially began over the weekend. to 1:30 p.m. Click here to learn more and sign up. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Biosimilars 75

Biosimilars Hospitals Pharmacy Drugs 75

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. d/b/a Drug Channels Institute. to 1:30 p.m.

Biosimilars 75

Biosimilars Pharmacy Drugs 75

Drug Channels

FEBRUARY 21, 2024

Below, I explain why the IRA will encourage Part D plans to prefer high-list, high-rebate specialty drugs , even as the government and manufacturers will prefer a low-list-price version. Just another IRA-inflicted hit for biosimilars? Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Biosimilars 98

Biosimilars Drugs Government Production 98

Drug Channels

DECEMBER 17, 2020

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021. Drug pricing perceptions always seem to lag reality. Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began. d/b/a Drug Channels Institute.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

Drug Channels

APRIL 20, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Growth in the number of excluded drugs slowed, due partly to the fact that so many drugs have already been dropped from PBMs’ formularies. d/b/a Drug Channels Institute.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

Drug Channels

APRIL 3, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The 2024 formularies described below should boost biosimilar adoption. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars 52

Biosimilars Pharmacy Drugs Production 52

FDA Law Blog: Biosimilars

JUNE 10, 2024

Last month the Department of Justice and the Drug Enforcement Administration submitted a notice of proposed rulemaking to reschedule cannabis from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. Hyman, Phelps & McNamara, P.C. Information and registration is available at the conference webpage here.

Regulations 59

Regulations Drugs Research 59

FDA Law Blog: Biosimilars

MARCH 12, 2023

We will discuss the state of relevant laws prior to our new “COVID reality” and telemedicine issues during and post-pandemic, both with respect to the prescribing of controlled substances and non-controlled drugs. Please see detailed information in the attached flyer , including a link to register for our free webinar.

Regulations 98

Regulations Government FDA Drugs 98

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Biosimilars 75

Biosimilars Drugs Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Biosimilars Drugs 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Biosimilars Drugs 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Biosimilars 74

Biosimilars Drugs Hospitals 74

Drug Channels

NOVEMBER 22, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy FDA Biosimilars 75

Drug Channels

MAY 29, 2024

Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Summer unofficially began over the weekend. All rights reserved.

Biosimilars 52

Biosimilars Drugs Marketing 52

FDA Law Blog: Biosimilars

JUNE 24, 2024

HPM) Director Dara Katcher Levy will present an informative webinar on the newly released AMCP Format for Formulary Submissions version 5.0. To register for this insightful webinar, visit AMCP Learn. This afternoon Hyman, Phelps & McNamara, P.C.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

FDA Law Blog: Biosimilars

MAY 3, 2023

Accounting for controlled substances, maintaining complete and accurate records/reports and employing effective, compliant security do not alone guarantee a successful Drug Enforcement Administration (“DEA”) inspection. The webinar will share additional valuable inspection tips. Hyman, Phelps & McNamara, P.C. (“HP&M”)

International 52

International Drugs 52

Drug Channels

NOVEMBER 24, 2020

In this issue: Rebate rule redux Most Favored Nation and healthcare benchmarking Amazon’s pharmacy customer opportunity Drug spending realities updated GPO consolidation Plus, I congratulate Dirk Rodgers of RxTrace on his retirement. Join me for an exclusive live webinar, Drug Channels Outlook 2021 , on December 18, 2020, from 12:00 p.m.

Pharmacy 52

Pharmacy Specialty Pharmacies Biosimilars Drugs 52

FDA Law Blog: Biosimilars

SEPTEMBER 12, 2023

More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.

Hospitals 49

Hospitals Pharmacy Compliance Government 49

Drug Channels

NOVEMBER 29, 2022

Please join me for my upcoming live video webinar, Drug Channels Outlook 2023 , on December 16, 2022, from 12:00 p.m. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. to 1:30 p.m. Click here to learn more and sign up.

Pharmacy 74

Pharmacy Drugs Marketing Biosimilars 74

FDA Law Blog: Biosimilars

MAY 22, 2023

Accounting for controlled substances, maintaining complete and accurate records/reports and employing effective, compliant security do not alone guarantee a successful Drug Enforcement Administration (“DEA”) inspection. Please see the attached flyer that includes a link to register for the webinar.

International 40

International Drugs 40

FDA Law Blog: Biosimilars

SEPTEMBER 26, 2023

More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.

Hospitals 45

Hospitals Pharmacy Compliance Government 45

Alta Sciences

JUNE 9, 2023

Accelerating Global Drug Development Timelines With Ethnobridging rmaloney Mon, 06/12/2023 - 16:07 HTML Safe Strategy to Save Time and Money Avoid repeating Phase I studies for drugs intended for the Asian market. Download your copy today. In this complimentary webinar , Mel B. Watch the webinar.

Drug Development 40

Drug Development Clinical Trials Pharmacokinetics Biosimilars 40

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Biosimilars Drugs 40

Agency IQ

OCTOBER 20, 2023

BsUFA III regulatory science pilot offers progress report, fields stakeholder criticisms and questions This week, FDA and its grantees briefed stakeholders on the status of research projects funded through the Biosimilar User Fee Act (BSUFA III) Regulatory Science Pilot Program. Developing biosimilars is an extensive and expensive process.

Science 40

Science Biosimilars FDA Production 40

Agency IQ

MARCH 1, 2024

There are also some product-specific bioequivalence guidelines open for comment, along with concept papers proposing the development of materials on the topics of biosimilar development and non-inferiority comparisons in clinical trials.

Regulations 40

Regulations Biosimilars Clinical Trials Production 40

Drug Channels

DECEMBER 1, 2020

distribution channels for prescription drugs. drug wholesaling industry. Speaking of next year, Drug Channels Institute will host an exclusive live webinar, Drug Channels Outlook 2021 , on December 18, 2020, from 12:00 p.m. d/b/a Drug Channels Institute. to 1:15 p.m. Click here to learn more and sign up.

Pharmacy 40

Pharmacy Drugs Vaccine Pharmaceuticals 40

Agency IQ

MAY 3, 2024

Many of these are webinars and/or trainings sessionsfor new digital platforms. This month will also see several large, multi-day conferences hosted by public and private stakeholders. Start Date End Date Event Event Type Organization 4/30/2024 4/30/2024 Seminar No.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40

Agency IQ

JULY 8, 2024

Several webinars and training sessions are geared towards ISO identification of medicinal products (IDMP) standards which is referred to as Substance, Product, Organization, Referentials (SPOR) data management services. ’s Medicines and Healthcare products Regulatory Agency (MHRA).

Regulations 40

Regulations Pharmaceuticals Production Vaccine 40

Agency IQ

MAY 31, 2024

Many of these webinars and trainings sessions are geared towards medical devices and in vitro diagnostics (IVDs). There will also be a number of noteworthy conferences taking place this month pertaining to the vaccine and medical technology industries.

Regulations 40

Regulations Production Compliance Pharmaceuticals 40

Agency IQ

OCTOBER 27, 2023

A wide range of other meetings that will be occurring this month, with various webinars, committee meetings, and workshops spanning a variety of topics. Upcoming Webinar Hosted by Xtalks Webinar/Seminar ( OPEN) Xtalks 11/6/2023 11/6/2023 What is the evidence for high-risk medical devices in the field of cardiovascular disease and diabetes?

Regulations 40

Regulations Pharmaceuticals Production Packaging 40

Agency IQ

MARCH 29, 2024

This will include a number of conferences, webinars, and training sessions, as well as a long-awaited EMA workshop on psychedelics. regulatory framework Webinar/ Seminar ( OPEN ) EMA 4/17/2024 4/17/2024 CEP 2.0: regulatory framework Webinar/ Seminar ( OPEN ) EMA 4/17/2024 4/17/2024 CEP 2.0:

Regulations 40

Regulations Production Clinical Trials Pharmaceuticals 40

Agency IQ

AUGUST 2, 2024

Major European regulators, national competent authorities, and interest groups are planning on hosting several webinars and trainings throughout August and September. Speaking of policy, legislative affairs will also likely pick up.

Regulations 40

Regulations Clinical Trials Production Trials 40